Sphingosine kinase (Sphk) has been shown to be activated by growth factor and survival factors, and one of its products, sphingosine-1-phosphate, plays an important role in the regulation of various cellular responses. However, the effect of Sphk on the maturation and immunostimulatory function of dendritic cells (DCs) still remains largely unknown. In this study, we examined whether sphingosine kinase inhibitor (SKI) can influence co-stimulatory molecules (CD40, CD80, CD86 and MHC class II) and cytokine production (IL-12 and IL-10) in murine bone marrow-derived DCs. SKI significantly inhibited co-stimulatory molecules in DCs. SKI suppressed IL-12 production by DCs and IFN-g production by T cells. In addition, SKI-inhibited LPS induced the translocation of nuclear factor-kB, whereas it did not affect the degradation of IL-1 receptor-associated kinase-1 by LPS. These novel findings provide new insight into the immunopharmacological role of SKI in terms of its effects on DCs. These findings open a possibility for further understanding of the immunopharmacological functions of SKI, as well as therapeutic adjuvants for the treatment of DC-related acute and chronic diseases.
Introduction
A considerable number of investigations are presently focused on the biology of bone marrow-derived dendritic cells (BMDCs) in terms of their possible clinical application as cellular therapies of chronic infections and cancers. BMDCs, as antigen-presenting cells, have a unique ability to enhance T and B cell responses as well as immune tolerance (1, 2) . Under steady state, DCs exist in peripheral tissue at an immature state where they exert a guard function for incoming antigens (1, 2) . Immature DCs do not enhance primary immune responses because they do not express the requisite co-stimulatory molecules and the antigenic peptides as stable complexes with MHC molecules. During pathogen invasion or after exposure to inflammatory cytokines, DCs undergo phenotypic change and functional maturation (3) . Upon maturation, DCs in peripheral tissues migrate into the afferent lymphatics and move to T cell area of draining lymph nodes through the signals of both MHC molecules presenting antigenic peptides and co-stimulatory molecules, and subsequently initiate adaptive immune responses (3, 4) .
Sphingosine-1-phosphate (S1P) has been shown to be associated with signals for calcium mobilization, cytoskeletal re-organization, chemotaxis and proliferation in immune cells (5) (6) (7) (8) . The level of S1P is tightly regulated by the balance between synthesis through sphingosine kinase (Sphk), irreversible cleavage by S1P lyase and reversible dephosphorylation to sphingosine by S1Ps. Until now, the biological activity of S1P in the immune system has been well understood. Recently, it is shown that cell migration and survival are enhanced by S1P (9) (10) (11) , whereas the S1P precursor ceramide can induce apoptosis (12) in DCs. Furthermore, S1P in maturing DCs promotes their capacity to induced T h type-2 immune response (9) and inhibit T cell proliferation (5) . However, the cellular targets of Sphk in DCs are not yet known, leaving the question of its global function in the maturation and immunoregulatory activities of DCs open.
Despite much effort in investigating sphingolipid signaling, there are very few established inhibitors of the enzymes of this pathway. In particular, the field suffers from a lack of potent and selective inhibitors of Sphk. Pharmacological studies to date have used sphingosine analogues, especially N.N-dimethylsohingosine (DMS) however these lipids are well-known to inhibit several protein kinases (13) (14) (15) (16) . Very recently, a few natural product inhibitors (compounds I-V) of Sphk have been isolated. It has been reported that compound II among the natural product inhibitors of Sphk is the most selective Sphk inhibitor and so may be the most attractive candidate for additional medicinal chemistry efforts (17) . In this study, we used compound II as sphingosine kinase inhibitor, namely SKI, to investigate the effect of a non-cytotoxic concentration of SKI on the maturation and function in BMDCs. SKI inhibits LPS-induced co-stimulatory molecules expression and allostimulatory function, indicating that SKI is a putative inhibitor of DC maturation. These findings provide new insight into the immunopharmacology of SKI and Sphk as a potential target. Taken together, these data suggest that SKI may have critical implications for the manipulation of the functions of DCs for potential therapeutic application.
Methods

Mice
Male 8-to 12-weeks-old C57BL/6 (H-2K b and I-A b ) and BALB/c (H-3K d and I-A d ) mice were purchased from the Korean Institute of Chemistry Technology (Daejeon, Korea). They were housed in a specific pathogen-free environment within our animal facility for at least 1 week before use.
Reagents and antibodies
Materials were obtained from the following sources: recombinant mouse (rm) granulocyte macrophage colonystimulating factor (GM-CSF) and rmIL-4 were purchased from R&D Systems. [c-32 P] ATP was purchased from Amersham Biosciences, SIP and sphingosine were obtained from Biomol (Plymouth Meeting, PA, USA), VPC23019 from Avanti (Alabaster, AL, USA) and SKI was purchased from Calbiochem (San Diego, CA, USA). Dextran-FITC (molecular mass, 40 000), mitomycin C and LPS (from Escherichia coli 055:B5) were obtained from Sigma (St. Louis, MO, USA); FITC-or PE-conjugated mAbs of CD11c (HL3), CD80 (16-10A1), CD86 (GL1), I-A b b-chain (AF-120.1) or IL-12 p40/ p70 (C15.6) and IL-10 (JESS-16E3), by flow cytometry; as well as isotype-matched control mAbs and biotinlyated antiCD11c (N418) mAbs were purchased from eBioscience (San Diego, CA, USA). Mouse anti-rabbit Sphk1 antibody was prepared as described previously (18) . Anti-IL-1 receptorassociated kinase (IRAK)-1, anti-p65 and anti-a-tubulin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Isolation and culture of DCs
DCs were generated from murine BM cells according to the procedure of Inaba et al. (19) with minor modification. Briefly, BM was flushed from the tibiae and femurs of 6-8 weeks male C57BL/6 and depleted of RBCs with Red Blood Cell Lysing buffer (Sigma). The cells were plated in six-well culture plates (1 3 10 6 cells ml À1 ; 2 ml per well) in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U ml À1 penicillin, 100 mg ml À1 streptomycin, 20 ng ml À1 rmGM-CSF and 10 ng ml À1 rmIL-4 at 37°C, 5% CO 2 . On day 3 and 5 of the culture, floating cells were gently removed and fresh medium was added. On day 6 of the culture, non-adherent cells and loosely adherent proliferating DC aggregates were harvested for analysis or stimulation, or, in some experiments, re-plated in 60-mm dishes (1 3 10 6 cells ml À1 ; 5 ml per dishes). On day 7, 80% or more of the non-adherent cells expressed CD11c. In certain experiments, to obtain highly purified populations for subsequent analysis, the DCs were labeled with bead-conjugated anti-CD11c mAb (Miltenyi Biotec, Gladbach, Germany) followed by positive selection through paramagnetic columns (LS columns; Miltenyi Biotec) according to the manufacturer's instruction. The purity of the selected cell fraction was >90%.
Expression vectors of Sphk
The expression constructs for human Sphk1 and for the dominant-negative mutant G82D of human Sphk1 cloned into vector pEGFP-C2 have been described previously (20) .
Determination of DC viability
SKI was added to cultures of isolated DCs in six-well plates (1 3 10 6 cells ml
À1
; 2 ml per well). For the determination of cell viability, DCs were stimulated with LPS or left without any stimuli, and viability was analyzed by double staining with 5 lg ml À1 propidium iodide (PI) and annexin-V, and then analyzed by flow cytometry.
Flow cytometry
On day 7, DCs were harvested, washed with PBS and resuspended in FACS washing buffer (2% FBS and 0.1% sodium azide in PBS). Cells were first blocked with 10% (v/v) normal goat serum for 15 min at 4°C and stained with PEconjugated mouse mAb against CD40, CD80, CD86 and MHC class II with FITC-conjugated CD11c for 30 min at 4°C, and then cells were analyzed on a FACSCalibur cytometer (Becton Dickenson). To calculate the percentage of positive cells, a proportion of 1% false-positive events were accepted in the negative control samples throughout.
Mixed leukocyte reaction assay
Responder T cells, which participate in allogeneic T cell reactions, were isolated when passed through mononuclear cells from BALB/c mice in a MACS column (Miltenyi Biotec). Staining with FITC-conjugated anti-CD3 antibodies (BD PharMingen, San Diego, CA, USA) revealed that they consisted mainly of CD3 + cells (>95%). The lymphocyte population (95% of CD3 + cells) was then washed twice in PBS and labeled with 5,6-carboxylfluorescein diacetate succinimidyl ester (CFSE), as previously described (21) . The cells were re-suspended in 5 lM CFSE in PBS. After being shaken for 8 min at room temperature, the cells were washed once in pure FBS and twice in PBS with 10% FBS. DCs (1 3 10 4 ) or DCs exposed to SKI (2.5 lM) or LPS (200 ng ml À1 ) for 24 h were co-cultured with 1 3 10 5 allogeneic CFSE-labeled T lymphocytes in 96-well, Ubottom plates (Nunc). A negative control (CD3 + lymphocytes alone) and a positive control (CD3 + lymphocytes in 5 lg of Con A) were created for each experiment. After 4 days, the cells were harvested and washed in PBS. CFSE dilution optically gated lymphocytes were assessed by flow cytometry.
Cytokines measurement
Culture supernatants were analyzed by ELISA. The OD 450 of triplicate sample was determined and corrected by a microplate reader, with reading at 570 nm. The minimum detections were as follows: IL-4, 7.8 pg ml À1 , and IFN-c, 31.3 pg ml À1 .
In vitro Sphk assay
The assay was performed as described by Olivera et al. (22) with minor modifications. Briefly, the cells were washed with ice-cold PBS and harvested by lysis buffer (20 mM Tris-Cl pH 7.4, 20% (v/v) glycerol, 1 mM mercaptoethanol, 1 mM EDTA, 1 mM Na 3 VO 4 , 15 mM NaF, 10 lg ml À1 leupeptin and aprotinin, 1 mM phenylmethylsulfonyl fluoride and 0.5 mM 4-deoxypyridoxine). Cells were lysed by freeze thawing three times, and cytosolic fractions were prepared by centrifugation at 13 000 3 g for 20 min. Equal amounts of protein were then incubated with 20 ll of kinase buffer containing 5 lM sphingosine, 1 mM ATP, 10 lci [c- , and then centrifuged at 3000 3 g for 5 min. The supernatant was aspirated, and the labeled lipids in the organic phase were then resolved on silica thin-layer chromatography plates (Merck) using 1-butanol/ethanol/acetic acid/ water (80:20:10:20) as the solvent system. Labeled S1P was visualized by autoradiography and quantified by phosphoimager or scraped and counted in a scintillation counter.
Transient transfection by electroporation
On day 5, DCs (2.0 3 10 6 cells per 100 ll of RPMI 1640 without serum and antibiotics) were mixed with DNA (5 lg per 400 ll of RPMI 1640 without serum and antibiotics). Electroporation was carried out using Electro Cell Manipulator 2001 (BTX), which delivers a square wave pulse. Immediately after electroporation, cuvettes were incubated on ice for an additional 10 min and then washed three times with cold PBS. After transfection, cells were seeded in six-well plates and incubated for 24 h prior to each experiments.
siRNA studies
DCs were transfected with 100 nM siRNA specific to hSphk1 (Santa Cruz Biotechnology) and a negative control siRNA according to the manufacturer's protocol (Santa Cruz Biotechnology). After a 24-h incubation, the cells were rinsed with PBS and used for further analysis as described above.
Western blot
DCs were washed twice with Tris-buffered saline and lysed by the addition of ice-cold lysis buffer, containing 0.5% Triton X-100, 50 mM Tris (pH 8.0), 150 mM NaCl, 5 mM EDTA, 5 mM NaF, 1 mM Na 3 VO 4 , 10 lg ml À1 aprotinin and pepstatin A and 5 lg ml À1 leupeptin. Lysates were left on ice for 20 min and centrifuged for 30 min at 12 000 3 g in a microcentrifuge at 4°C to remove nuclei. To examine the effect of SKI on nuclear factor-jB (NF-jB) nuclear translocation, nuclear proteins were extracted using NE-PERTM nuclear reagents (Pierce). Proteins were separated on 10% SDS-polyacrylamide gels and transferred to polyvinylidene difluoride membranes. Membranes were blocked with 5% non-fat dried milk in T-PBS (0.2% Tween 20 in PBS) and incubated with antibody against Sphk1, IRAK-1, NF-jB p65 or a-tubulin for overnight. Membranes were subsequently washed and incubated for 1 h with secondary antibody conjugated to HRP. Immunolabeling was detected using an enhanced chemiluminescence detection system (Millipore Corporation, Billerica, MA, USA).
Statistical analysis
Experiments were repeated at least three times with consistent results. Unless otherwise stated, data are expressed as the mean 6 SEM. Analysis of variance was used to compare experimental groups with control values. While comparisons between multiple groups were done using Tukey's multiple comparison test. Statistical significance was determined as P value < 0.05.
Results
LPS stimulates Sphk activity in BMDCs
In order to determine whether endogenous Sphk is expressed in immature or mature DCs, we measured Sphk1 expression by western blot analysis using anti-rabbit Sphk1 antibody. To obtain the lysates for immature DCs, cells were harvested on day 6 after culture with GM-CSF and IL-4. For the lysates for mature DCs, cells were harvested after treatment with 200 ng ml À1 LPS for 24 h on day 6. Expression of Sphk1 (49 kDa) was detected in both immature and mature DCs and LPS maturation did not cause any substantial change in the level of Sphk1 expression compared with immature DCs (Fig. 1A) . Next, to investigate whether LPS affected Sphk activity in immature DCs, we analyzed Sphk activity after LPS stimulation in immature DCs. We found that LPS stimulated Sphk activity in a time-dependent manner. LPS-induced Sphk activation reached a maximum value (1.87-fold induction) at 60 min after LPS stimulation and decreased slightly thereafter (90-120 min) (Fig. 1B ). An induction of Sphk in the same order of magnitude (;2-fold induction) was recently described by Wu et al. (23) in LPSactivated macrophages, and is also generally seen in at the same level in some other cell types when induced a variety
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To exclude the possibility that impairment of DC function mediated by SKI is due to a reduction of DC numbers through apoptosis, we tested apoptotic sensitivity of DCs to SKI. On day 6 of DC cultures, SKI at a various concentration (0, 1, 2.5 and 5 lM) was pre-incubated for 3 h and then incubated with or without 200 ng ml À1 of LPS for a further 24 h. Because concentrations of SKI >5 lM were found to be somewhat cytotoxic to DCs, SKI was used at concentration <2.5 lM. There were no marked differences observed until reaching a concentration of 2.5 lM in the percentage of dead cells according to the CD11c + cells and annexin-V-PI staining (Fig. 1C) . Recently, it has been demonstrated that SKI acts as a highly specific inhibitor of Sphk (Inhibitory concentration at 50% = 0.5 lM for GST-human sohingosine kinase) and does not affect the kinase activity of hERK2, hPI3K or PKCa even at concentrations at high as 60 lM (17) . We tested whether SKI could inhibit LPS-stimulated Sphk activity in DCs. When DCs were pre-treated with 2.5 lM SKI, LPS-induced Sphk activation was blocked (2.06-fold reduction) (Fig. 1D) . 
SKI inhibits the expression of co-stimulatory molecules and IL-12 production but not IL-10 in LPS-stimulated DCs
To determine whether SKI would affect LPS-induced costimulatory molecules, the levels of co-stimulatory molecules were measured in LPS-treated DCs with or without SKI. As shown in Fig. 2(A) , stimulation of cells with LPS for 24 h from day 6 resulted in the up-regulation of co-stimulatory molecules ( Fig. 2A-b , f, j and n). It was found that 2.5 lM SKI Fig. 2 . SKI suppresses co-stimulatory molecules and IL-12 production during DC maturation. BMDCs were generated as described in Methods. (A) DCs were pre-incubated with SKI for 3 h and then further incubated with 200 ng ml À1 LPS for 24 h. Co-stimulatory molecules were then analyzed by flow cytometry. The cells were gated on CD11c 
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+ cells in LPS-treated DCs ( Fig. 2A-d , h, l and p). These data suggest that SKI-treated DCs were at least partially resistant to phenotype maturation. Specific cytokine patterns, IL-12 and IL-10, are known to select T h 1 and T h 2 dominant states of T cell-mediated immune responses, respectively (26) . Matured DCs treated with LPS produced IL-12 to regulate the T h 1 response (27) . IL-23, a more recently discovered member of the IL-12 family, also promotes T h 1 response, but has distinct functions from IL-12. IL-23 is a heterodimeric cytokine composed of the p40 and p19 subunits. While the p19 subunit is unique for IL-23, Fig. 3 . Continued   Fig. 3 . Over-expression of Sphk1 enhances co-stimulatory molecules and IL-12 production during DC maturation. BMDCs were generated as described in Methods. On day 5, DCs were transfected with either vector, SPHK1 or SPHK1(G82D), as described in Methods. (A) DCs were seeded in six-well-containing glass cover slips for overnight. On day 6, cover slips were fixed with 4% PFA for 15 min and mounted with 4#,6-diamidino-2-phenylindole-contained mounting medium to stain nucleus. (B) DCs over-expressing either vector, SPHK1 or SPHK1(G82D), were incubated with or without LPS (200 ng ml (28, 29) . IL-23 is required for the generation of effector memory T cells (28) . IL-23 is also needed for the generation of IL-17-producing T cells which play a significant role in the inflammatory response (30) . Through these activities, IL-23 plays a critical role in chronic inflammatory diseases. To assess whether SKI may modulate LPS-induced production of IL-12 or IL-10 in DCs, the respective productions of IL-12 and IL-10 were detected by flow cytometry. FITC-labeled anti-CD11c + DCs with PE-labeled anti-IL-12 p40/p70 or PE-labeled anti-IL-10 mAbs indicated that LPS-treated DCs in the presence of SKI expressed a low level of IL-12 p40/p70 (Fig. 2B-d ) compared with those of LPS-treated DCs in the absence of SKI (Fig. 2B-b) , whereas IL-10 was not detected (Fig. 2B-f and h ). These findings suggest that SKI attenuated the capability of DC to enhance high levels of IL-12p40p70. Taken together, these phenomena demonstrate that SKI suppresses the maturation function of DCs stimulated with LPS.
The expression of co-stimulatory molecules and IL-12 production were enhanced in DCs over-expressing Sphk1
To test directly the idea that Sphk, especially Sphk1, may have influence on LPS-induced expression of co-stimulatory molecules and cytokine production, cells were transfected with vectors expressing green fluorescent protein (GFP)-tagged human Sphk1, namely SPHK1, or dominant-negative Sphk1, namely SPHK1(G82D), in DCs. First, to confirm the transfection efficiency in our system, we measured the level of GFP expression analyzed by fluorescence microscopy. The expression of GFP was clearly visualized in DCs transfected with either vector, SPHK1 or SPHK1(G82D) (Fig. 3A) .
Furthermore, we measured percentage of survival of DCs over-expressing either vector, SPHK1 or SPHK1(G82D), after stimulation with or without LPS for 24 h. There were no marked differences in the percentage of dead cells according to the annexin-V-PI staining (Fig. 3B) . Next, we sought to determine whether DCs over-expressing either vector, SPHK1 or SPHK1(G82D), influenced Sphk activity. Therefore, we measured Sphk activity in DCs over-expressing either vector, SPHK1 or SPHK1(G82D), in the presence and absence of SKI after LPS stimulation. As shown in Fig. 3(C) , the activation of Sphk after LPS stimulation was about the same as those activated by the parental cells or vectortransfected cells (black bars in DCs and vector transfectant). However, LPS-induced Sphk activation was even higher in DCs over-expressing SPHK1 without changing the kinetics (white and black bars of SPHK1 transfectant). The fold increase in Sphk activity by LPS in DCs over-expressing SPHK1 (407.6 6 60.4%) (black bar of SPHK1 transfectant) was almost twice of those in parental cells (223.3 6 16.44%) (black bar of DCs) or vector-transfected cells (215 6 7.63%) (black bar of vector transfectant), and LPS-induced Sphk activation was strongly inhibited in DCs over-expressing SPHK1(G82D) (70.3 6 12.06%) (black bar of SPHK1(G82D) transfectant). Additionally, the induction of Sphk activity in parental cells or DCs over-expressing vector, SPHK1 or SPHK1(G82D), was completely diminished below the baseline by SKI treatment (all gray bars).
As shown in Fig. 3(D) , the expression of co-stimulatory molecules was completely inhibited in DCs over-expressing SPHK1(G82D) (Fig. 3D-f , l, r and x) even after LPS stimulation, compared with the corresponding vector transfectant (Fig. 3D-b , h, n and t) or SPHK1 transfectant (Fig. 3D-d,   Fig. 3 . Continued j, p and v). Interestingly, co-stimulatory molecules were clearly enhanced in DCs over-expressing SPHK1 even after no LPS stimulation (Fig. 3D-c, i, o and u) . The enhancement of maturation in DCs over-expressing SPHK1 even if no LPS stimulation was used is likely due to the increased production of S1P.
Furthermore, we found that the production of IL-12 p40/ p70 was significantly enhanced in DCs over-expressing SPHK1 even without LPS stimulation (Fig. 3E-c) compared with the corresponding vector transfectant (Fig. 3E-a) or SPHK1(G82D) transfectant (Fig. 3E-e) . However, the production of IL-12 p40/p70 was completely inhibited in LPS-treated DCs over-expressing SPHK1(G82D) (Fig. 3E-f ) compared with the corresponding vector transfectant (Fig. 3E-b) or SPHK1 transfectant (Fig. 3E-d) . Our finding suggested that Sphk1 may affect T cell-mediated responses by provoking DCs to release T h 1-promoting cytokines, such as IL-12.
SKI impairs the allostimulatory capacity of DCs CFSE, a fluorescein-based dye, has biochemical properties that render it particularly appropriate for this application. Specifically, CFSE dye is loaded into cells in vitro, and the CFSE in a given cell is monitored over time. The CFSE segregates equally between the daughter cells on division, such that the intensity of cellular fluorescence decreases 2-fold with each successive generation. This property of CFSE allows for the accurate tracking of the number of divisions that a given cell has undergone, either in vitro or following transfer in vivo (31) . In order to determine whether SKI exerts detectable effects on allogeneic T cell stimulation, we subjected the DCs to 24 h of stimulation with SKI.
As shown in Fig. 4(A) , the rate of proliferation of allogeneic T cells elicited by LPS-treated DCs (Fig. 4A-e) appeared to be faster than that of in untreated DCs (Fig. 4A-b) , whereas The treated DCs were harvested and thoroughly washed to remove all SKI. A mixed lymphocyte reaction was allowed to proceed for 4 days, as described in Methods. (B) Clustering was assessed after 64 h. (C) The cells were then examined for cytokine release after 48 h using ELISA. Medium represents the chemically untreated control group. (D) DCs were transfected with Sphk1 siRNA at a concentration of 25, 50 and 100 nM, no siRNA (Mock) or control siRNA (Con) for 24 h, and then cells were harvested. The level of Sphk1 and a-tubulin were determined by western blotting. (E) DCs were transfected with Sphk1 siRNA (100 nM), no siRNA (Mock) or control siRNA (Con) for 24 h, and then further incubated with LPS for 24 h. DCs were harvested and washed. A mixed lymphocyte reaction was allowed to proceed for 4 days, as described in Methods. (F) DCs were transfected with Sphk1 siRNA (100 nM), no siRNA (Mock) or control siRNA (Con) for 24 h, and then further incubated with LPS for 24 h. The cells were then examined for cytokine release after 48 h using ELISA. Values indicate mean 6 SEM obtained from at least three separate experiments (C and F). The results were from one representative experiment of three performed (A, B, D and E). The asterisks in panel (C) and (F) indicate significant increases compared with that of LPS treatment at **P < 0.01, ***P < 0.001 and P > 0.05 (n.s., not significant).
SKI appeared to inhibit proliferation responses in the allogeneic T cells elicited by the LPS-stimulated DCs (Fig. 4A-f) . These findings suggest that the maturation induced by LPS stimulation (24 h of 200 ng ml À1 ) profoundly promoted the allostimulatory capacity of the untreated DCs, whereas exposure to SKI significantly inhibited their allostimulatory capacity.
We also attempted to determine the potency of DCs in terms of their ability to adhere to T cells, and thus form clusters. The size of the DC/T cell clusters diminished with exposure to SKI as compared with what was observed in the LPS-treated cells (Fig. 4B) . In the presence of SKI (Fig. 4B-d) , the LPS-treated DCs formed clusters that were 60% of the size of the clusters formed by the LPS-stimulated DCs in the absence of SKI (Fig. 4B-b) . Considering the inhibitory effects of SKI on the production of IL-12 (a T h 1-inducing cytokine) in DCs, we attempted to characterize the quality of the primary T cell response in DCs that had matured in the presence of SKI. Naive allogeneic T cells primed with mature DCs were observed to differentiate into T h 1 lymphocytes when they generated high levels of IFN-c and low levels of IL-4 (Fig.  4C) . In contrast, T lymphocytes primed with DCs that had matured in the presence of SKI-inhibited LPS-induced IFN-c production.
To verify the allostimulatory capacity of DCs through Sphk1-dependent signaling, DCs were transfected with Fig. 4 . Continued Sphk1-specific siRNA and then measured the rate of proliferation of allogeneic T cells (Fig. 4E ) and the levels of IFN-c or IL-4 (Fig. 4F) . Western blotting verified that the expression of Sphk1 was specifically and significantly reduced by the cognate Sphk1 siRNA duplex compared with mock transfections or transfections with a control siRNA (Fig. 4D) . Importantly, compared with mock transfections (Fig. 4E-f ) and control siRNA transfections (Fig. 4E-g ), Sphk1 siRNA (Fig. 4E-h ) significantly reduced proliferation responses in the allogeneic T cells elicited by the LPS-stimulated DCs and also inhibited LPS-induced IFN-c production (Fig. 4F) . These results show that the majority of the effects of SKI on the T cell differentiating properties of DCs are a consequence of the inhibition of IL-12 production.
SKI inhibits the activation of NF-jB, but not the upstream signaling components of IRAK-1 including MyD88.
NF-jB activation is an important event underlying DCs maturation (31) . Also, LPS stimulation has been shown to activate NF-jB signal pathways in DCs (32) . To gain insight into Sphk-induced signaling, we determined whether NF-jB might be involved in Sphk-induced signaling pathways in DCs. To determine whether SKI decreases LPS-induced activation of NF-jB, nuclear translocation of the NF-jB p65 subunit was performed. Pre-treatment with SKI suppressed the NF-jB p65 nuclear translocation that was induced by LPS stimulation (Fig. 5A) . The stimulation of toll-like receptor (TLR)-4 with agonists enhances the homodimerization of TLR4 leading to the recruitment of MyD88. MyD88 induces the phosphorylation of IRAK-4, which in turn phosphorylates IRAK-1 leading to the degradation of IRAK-1 and the activation of NF-jB signal pathways. Thus, IRAK-1 degradation was used as an additional read out for the activation of TLRs. SKI did not inhibit LPS-induced degradation of IRAK-1 (Fig. 5B) . MyD88 is the upstream molecule which enhances the phosphorylation and degradation of IRAK-1. Therefore, our data suggest that SKI does not inhibit MyD88. These results suggest that the molecular target of SKI is not the upstream signaling components of IRAK-1 including MyD88, but is the upstream molecules of NF-jB signal pathways.
S1P produced by LPS acts intracellularly on DCs maturation
Recent evidence suggests that S1P regulates the production of cytokines in different cell types (33, 34) . However, Idzko et al. (9) and Renkl et al. (35) reported that S1P did not effect basal cytokine production such as IL-12 and IL-10 from immature DC. To investigate whether S1P produced by Sphk1 can act extracellularly through its specific G-protein-coupled receptors binding or intracellularly as second messenger. First, we applied S1P extracellularly, and then measured costimulatory molecules and cytokine production in DCs. S1P at a concentration of 0.1 and 1 lM for 24 h had no influence on co-stimulatory molecules (Fig. 6A ) and cytokine production (Fig. 6B) in DCs. Next, to explore the candidate receptors involved in S1P-mediated co-stimulatory molecules and cytokine production, we used VPC23019, an inhibitor of S1P1 and S1P3. VPC23019, a S1P-related synthetic compound, is a very useful agent for examining the involvement of S1P, since it acts as a competitive inhibitor of S1P1 and S1P3, but partly stimulates S1P4 and S1P5 (36) . We measured co-stimulatory molecules and cytokine production by LPS in the presence and absence of VPC23019 (1 lM). LPS-induced co-stimulatory molecules and cytokine production were not significantly changed in DCs in the presence and absence of VPC23019 (Fig. 6C and D) . These data suggest that S1P produced by LPS might act intracellularly on DCs maturation independent of S1PR.
Discussion
This is, to the best of our knowledge, the first description of the effects of SKI on the phenotypic and functional maturation of murine BMDCs. In addition, this is the first study in which SKI-exposed DCs have been analyzed with regard to their capacity to sensitize recipients for cell-mediated immune responses. Sphk has been generally considered a cytosolic protein that is constitutively active, thus generating basal levels of S1P within the cells. S1P produced by Sphk can regulate various cellular process including growth, survival, differentiation, cytoskeleton rearrangements, chemotaxis, angiogenesis and immunity (37) (38) (39) . Although it is clear that SIP can modulate various physiological processes in the literature, it is not clear that the effects of Sphk1 on the maturation and immunological responses of DCs.
DCs are considered to play an important role in deciding the establishment of immunity and tolerance. (40, 41) . Thus, we performed a series of functional assays to ascertain the phenotype and function of SKI in murine BMDCs. To confirm that the observed effects of SKI could be attributed to DCs and not to contaminating cells persisting in the BMDC cultures, DCs were purified (>95%) prior to analysis in each of the conducted assays. Our findings indicated that SKI is a potent inhibitor of LPS-induced DC maturation. LPSinduced DC maturation was inhibited by SKI. The acute suppressive effects of SKI on DC maturation can be attributed to a non-specific inhibitory effect. Therefore, we also measured that the level of co-stimulatory molecules present after LPS stimulation in DC over-expressing either vector, SPHK1 or SPHK1(G82D), to determine the effect of Sphk1 on the maturation of DCs. The level of co-stimulatory molecule stimulated by LPS in DC over-expressing SPHK1(G82D) was Fig. 6 . LPS stimulates co-stimulatory molecules and IL-12 production in S1P receptor-independent pathway. BMDCs were generated as described in Methods. (A) DCs were incubated with S1P and LPS for 24 h. Co-stimulatory molecules were then analyzed by flow cytometry. The cells were gated on CD11c found to be significantly attenuated, whereas that in DCs over-expressing SPHK1 was strongly enhanced even if no LPS stimulation occurred, thereby suggesting that Sphk1 regulated both the phenotypic and functional maturation of DCs.
Recently collected evidence suggests that the production of cytokines by DCs is dependent on either the specific type of DC, or on the stimuli received by DC (42) . IL-12, in particular, exerts multiple immunoregulatory functions, inducing the activation of the T h 1 subset, which performs a critical role in the induction of inflammation (43, 44) . The results obtained in this report indicated that Sphk1 caused CD11c + DC to generate IL-12 in the presence of LPS, and also confirmed that SKI or DCs over-expressing SPHK1(G82D) exert inhibitory effects on the expression of intracellular IL-12 p40/p70.
In addition, this study shows that LPS-stimulated CD11c + DCs skewed naive T cells toward developing into IFN-c-producing T cells. SKI was determined to significantly impair the capacity of these cells to proliferate and initiate T h 1 (45) (46) (47) . Considering the practical development for inducing of T h 1 responses such as ex vivo manipulation of DCs and cytokine therapy for adaptive transfer, our newly discovered resullts suggest that T h 1-polarizing roles of Sphk1 may provide rationale for another target of DC based-therapies. Because T h 1 cells exert functionally immunogenic or defensive effects against invading pathogens, the inhibition of DC-mediated T h 1 polarization might constitute a SKIassociated immunosuppressive mechanism. However, the inhibition of T h 1 development exerts negative regulatory roles on a wide variety of immune cells (48) . Consequently, SKI-mediated inhibition of IL-12 generation in LPS-stimulated CD11c + DCs may also contribute to the induction of an immunosuppressive state.
Involvement of NF-jB in tumor necrosis factor a signaling via the Sphk pathway had been previously suggested in endothelial cells, based on the suppression of NF-jB activation by DMS (49) and on the activation of NF-jB by S1P (49, 50) . More recently, Wu et al. (23) reported that NF-jB activation by LPS in murine macrophages, as measured by transcriptional activity in a reporter gene assay, was inhibited by over-expression of a dominant-negative mutant of SPHK1. Our results suggest that NF-jB may be the target of inhibition by SK1 in DC maturation that results from impairing the translocation of NF-jB by SKI.
TLRs induce innate immune responses that are essential for host defense against invading microbial pathogens (51). In general, TLR activation triggers the activation of two downstream signaling pathways, MyD88-dependent and MyD88-independent pathways (52). TLR4 stimulates both MyD88-and TIR domain-containing adaptor-inducing IFN-b (TRIF)-dependent pathways while TLR2 and TLR3 stimulate MyD88-and TRIF-dependent signaling pathway, respectively. MyD88 recruits IRAK-4 and induces IRAK-4 phosphorylation. The phosphorylated IRAK-4 induces the phosphorylation of IRAK-1 leading to the degradation of IRAK-1 and the activation of NF-jB signal pathways. The activation of NF-jB leads to the induction of inflammatory gene products including cytokines. If SKI impairs the interaction of LPS with the receptor, it should inhibit the dimerization of TLR4 and the degradation of IRAK-1. LPS-induced degradation of IRAK-1 was not inhibited by SKI in DCs (Fig. 5B) . Our results suggest that SKI does not inhibit the interaction of LPS with TLR. In this context, our study shows for the first time that Sphk activation is not the component in the upstream of IRAK-1, including TLR4 or MyD88, but the upstream molecule such as NF-jB. S1P which is present in high concentration in serum and is also secreted by inflammatory cells has been known to play roles in allergic reactions and tumor pathogenesis (53, 54) . Biological activities and signaling pathways of S1P are mediated in a S1P receptor-dependent manners in DCs, T cells and NK cells in various lymphoid tissues (55) . Interestingly, in comparison to those reports, we observed that extracellular treatment with S1P on DCs did not affect the expression of co-stimulatory molecules or IL-12 production of immature and mature DCs, and inhibition of S1P receptors by VPC23019 (competitive antagonist to S1P1 and S1P3 receptors) also had no effect. Furthermore, although there have been raised a massive discrepancy regarding the function of intracellular and extracellular S1P, our findings in this issue strongly support that, at least in the DCs, by the LPSinduced high-level induction of intracellular Sphk and its metabolite, S1P, DCs can be directed to maturation in the end.
In this study, we demonstrated that the effect of SKI inhibit the maturation of mouse BM-derived myeloid DCs. At nontoxic concentration, SKI proved to be a potent inhibitor of DC maturation. This inhibitory effect of SKI on DC maturation is associated with suppressed translocation of NF-jB as potential target.
In conclusion, we have characterized a variety of effects exerted by SKI on BMDCs. SKI was demonstrated to inhibit phenotypic maturation and modulate cytokine production in these DCs, resulting in a significant inhibition of T h 1 development. Moreover, our experimental data showed that SKI suppressed LPS-induced co-stimulatory molecules and IFN-c. These findings illustrate the immunopharmacological functions of SKI. Moreover, exposure to this readily available drug may constitute a non-toxic and highly effective means for the modulation of DC immunostimulatory capacity. 
